Biomm’s Executive Directors, the Company‘s legal representatives are elected by the Board of Directors for a period of two years.
In accordance with the Brazilian Corporate Law, all are residents of Brazil.
The Executive Board is responsible for the business administration and complying with and enforcing the Bylaws and resolutions of the Board of Directors and the General Meeting. The board is also responsible for preparing and proposing business, operational and the Company‘s investment plans, as well as their budget.
Biomm’s Executive Board consists of:
Chief Executive Officer: Heraldo Carvalho Marchezini
Heraldo Marchezini has over 20 years of solid experience in the pharmaceutical market in various therapeutic segments. Senior VP of the Sanofi Group’s Latin America Region, holding the Presidency of the Brazilian Operation from February 2011 to July 2013 and is responsible for coordinating all the Group‘s companies in the Region: Pasteur, Genzyme and Merial. Member of the Sanofi Group’s Core Leadership Team. Member of the Global Pharma Operations Committee. General Director of Sanofi Group’s Brasil Sanofi and Medley (from May 2009 to July 2013) - General Director of Brasil Sanofi Aventis (September 2004 to April 2009) - General Director of Aventis Brasil (February 2004 to August 2004) - General Manager of Poland and the Netherlands - Aventis (March 2001 to February 2004) - Director of the Oncology Hospital Business Unit Rhodia Pharma and Aventis Brasil (September 1998 to February 2001). Vice President of SINDUSFARMA since 2009. President of ABIMIP during the period of 2009/2010. Vice-President of INTERFARMA from 2005 to 2007. CEO partner HR Você S.A. Magazine 2012. Recognized as "Executivo Valor" for the Pharmaceutical Segment by the Valor Econômico newspaper in 2012 and 2013.
Chief Operating Officer: Francisco Carlos Marques de Freitas
Electrical engineer graduated from UFMG in 1977, specialized in Industrial Electronics (UFMG, 1978). Graduated in Business Administration from the University of Pennsylvania, USA (1992). He attended the Advanced Management Program at INSEAD, France (1996). Project Engineer in Telemig (1977-1978). Participated in associations such as ISPE - International Society of Pharmaceutical Engineers and PDA - Parenteral Drug Association. He held the following positions in Biobrás: Executive Board member from 1995 to January 2002, Electrical Engineering Supervisor, Maintenance Manager, Engineering Manager and Industrial Superintendent. Significant experience in public procurement and international negotiations.
Technology Director: Luciano Vilela
Chemical Engineer graduated from UFMG in 1976. He participated in courses and worked as a visiting scientist in several internationally renowned institutions such as the GBF (Braunschweig, Germany) and Royal Institute of Technology (Stockholm, Sweden). He worked in Biobrás since 1976 as Director of the Technological Development. Its experience in Biobrás includes conceptualization and scheduling of equipment, products, and processes for the production of animal and purified recombinant human insulin and other proteins. Co-inventor of the recombinant human insulin manufacturing technology, with recognized patent by the USPTO. Author of numerous articles.
CFO and Investor Relations Officer: Douglas de Carvalho Lopes
Douglas has solid experience in the development and monitoring of projects, as well as the development of strategic planning. Also has experience in IT, purchasing and marketing. He was Director of Marketing and Operations (COO) of the IBMEC EDUCATIONAL GROUP from Feb/12 to Aug/13 being responsible for operations - Development and business plan review; Planning and execution of the expansion; Review and implementation of new operational processes. Purchasing - Structuring, department assembly and setting up, policies and procurement procedures; Review and negotiation of major contracts. Information Technology - Definition and implementation of the new academic system; Definition and implementation of new CRM; IT - Review of IT strategy. Marketing - Review of the structure and focus of the area; Developing new marketing campaign; Creating a new Ibmec and Metrocamp portal. He was also the MONITOR GROUP’s Senior Manager from Sep/07 to Jan/12, responsible for developing the strategic planning and evaluating strategic acquisitions; Structuring and development of the commercial plan; Development of new organizational structures; Definition of financial strategies, optimal capital structure and development of valuation models; Also worked in the automotive market (GM and FIAT) within the Procurement and Logistics department for a few years.
Douglas is a Mechanical Engineer graduated from the POI-USP, with specialization in business administration from FGV-SP (CEAG) and MBA from MIT Sloan.
Commercial Director: Ciro Enrique Massari
Graduated in Biochemistry Pharmacy from UNESP - Araraquara; Post Graduated in Business Administration from the São Luís College and MBA from ESPM 1995 - Dec 2014 - Director of Strategic Planning and Innovation - Sanofi Farma Brasil, being responsible for Strategic Planning and Innovation for the corporate level by integrating the knowledge of the business with the vision of products, processes and people - Fev 2013 - Mar 2014 - Director of Generics and Brand Generics - Sanofi Mexico, responsible for the start-up of Medley Generics and the Medley brand in the country, developing business plans and strategies for the Mexican market - Jul 2009 - Jan 2013 - Director of Marketing and Sales of Internal Medicine - Sanofi Farma Brasil, • Director of the mature products business unit, leading a marketing team of 30 people and 400 medical representatives, responsible for the Unit’s "Profit & Loss". • Established a dedicated team to work with Rheumatoid Arthritis facing strong competition from AntiTNF, together with doctors and the public service using American and European "guidelines" - May 2008 - Jun 2009 - Marketing and Sales Manager Hospital Line - Sanofi Farma Brasil - Feb 2007 - Apr 2008 - National Sales Manager Hospital Line - Sanofi Farma Brasil - Feb 2005 - Jan 2007 - Regional Manager of Medical Promotion - "PrimaryCare" Line - Jan 2002 - Jan 2005 - Oncology Product Manager - Feb 2000 - Dec 2001 - Oncology District Manager - São Paulo/South - Jan 1998 - Dec 1999 - Oncology Medical Representative - Jan 1996 - Dec 1997 - Medical Representative - Hospital - Aug 1995 - Dec 1995 - Medical Representative - "PrimaryCare".
he Board of Directors consists of 8 Directors who have the primary duty the Company‘s guidance and strategic planning. The Board of Directors is also responsible for outline the Company’s general policies and guidelines and perform the duties conferred to them by the Brazilian Corporation Law.
The Board of Directors current members are:
|Guilherme Caldas Emrich||Chairman||04.29.2016|
|Ítalo Aurélio Gaetani||Member||04.29.2016|
|Walfrido Silvino dos Mares Guia Neto||Member||04.29.2016|
|Luiz Francisco Novelli Viana||Member||04.29.2016|
|Eduardo Augusto Buarque de Almeida||Member||04.29.2016|
|Leandro Alberto Torres Ravache||Member||04.29.2016|
|Marco Aurélio Crocco Afonso||Member||04.29.2016|
|Cláudio Luiz Lottenberg||Member||04.29.2016|
|Dirceu Brás Aparecido Barbano||Member||08.21.2017|
Last Update on August 21, 2017